Literature DB >> 15095978

P53 inhibits strand exchange and replication fork regression promoted by human Rad51.

Dennis Yoon1, Yuzhen Wang, Kenneth Stapleford, Lisa Wiesmüller, Junghuei Chen.   

Abstract

We explore the effects of p53 on strand exchange as well as regression of stalled replication forks promoted by human Rad51. We have found that p53 specifically inhibits strand exchange mediated by human Rad51, but not by Escherichia coli RecA. In addition, we provide in vitro evidence that human Rad51 can promote regression of a stalled replication fork, and p53 also inhibits this fork regression. Furthermore, we show that two cancer-related p53 mutant proteins cannot inhibit strand exchange and fork regression catalyzed by human Rad51. The results establish a direct functional link between p53 and human Rad51, and reveal that one of p53's functions in genome stabilization may be to prevent detrimental genome rearrangements promoted by human Rad51. Thus, the results support the hypothesis that p53 contributes to genome stability by a transcription-independent modulation of homologous recombination.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15095978     DOI: 10.1016/j.jmb.2003.12.050

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  28 in total

Review 1.  Pathways of mammalian replication fork restart.

Authors:  Eva Petermann; Thomas Helleday
Journal:  Nat Rev Mol Cell Biol       Date:  2010-09-15       Impact factor: 94.444

2.  DNA repair after irradiation in glioma cells and normal human astrocytes.

Authors:  Susan C Short; Christine Martindale; Sara Bourne; Geoff Brand; Mick Woodcock; Peter Johnston
Journal:  Neuro Oncol       Date:  2007-08-17       Impact factor: 12.300

3.  Fork regression is an active helicase-driven pathway in bacteriophage T4.

Authors:  David T Long; Kenneth N Kreuzer
Journal:  EMBO Rep       Date:  2009-03-06       Impact factor: 8.807

4.  p53 and the PWWP domain containing effector proteins in chromatin damage repair.

Authors:  Jing Hu; Yanming Wang
Journal:  Cell Dev Biol       Date:  2013-05-10

5.  RAD51 135G>C and TP53 Arg72Pro polymorphisms and susceptibility to breast cancer in Serbian women.

Authors:  Ana M Krivokuca; Emina J Malisic; Jelena D Dobricic; Ksenija V Brotto; Milena R Cavic; Radmila N Jankovic; Zorica I Tomasevic; Mirjana V Brankovic-Magic
Journal:  Fam Cancer       Date:  2014-06       Impact factor: 2.375

6.  Triapine disrupts CtIP-mediated homologous recombination repair and sensitizes ovarian cancer cells to PARP and topoisomerase inhibitors.

Authors:  Z Ping Lin; Elena S Ratner; Margaret E Whicker; Yashang Lee; Alan C Sartorelli
Journal:  Mol Cancer Res       Date:  2014-01-10       Impact factor: 5.852

7.  Sequence-specific correction of genomic hypoxanthine-guanine phosphoribosyl transferase mutations in lymphoblasts by small fragment homologous replacement.

Authors:  Babak Bedayat; Alireza Abdolmohamadi; Lin Ye; Rosalie Maurisse; Hooman Parsi; Jennifer Schwarz; Hamid Emamekhoo; Janice A Nicklas; J Patrick O'Neill; Dieter C Gruenert
Journal:  Oligonucleotides       Date:  2010-02

8.  RAD51 variant proteins from human lung and kidney tumors exhibit DNA strand exchange defects.

Authors:  Michelle C Silva; Milagros D Morrical; Katie E Bryan; April M Averill; Julie Dragon; Jeffrey P Bond; Scott W Morrical
Journal:  DNA Repair (Amst)       Date:  2016-04-25

9.  p53 isoform Δ113p53/Δ133p53 promotes DNA double-strand break repair to protect cell from death and senescence in response to DNA damage.

Authors:  Lu Gong; Hongjian Gong; Xiao Pan; Changqing Chang; Zhao Ou; Shengfan Ye; Le Yin; Lina Yang; Ting Tao; Zhenhai Zhang; Cong Liu; David P Lane; Jinrong Peng; Jun Chen
Journal:  Cell Res       Date:  2015-02-20       Impact factor: 25.617

10.  Secondary structure formation and DNA instability at fragile site FRA16B.

Authors:  Allison A Burrow; Allison Marullo; Lindsay R Holder; Yuh-Hwa Wang
Journal:  Nucleic Acids Res       Date:  2010-01-13       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.